The prostanoid analog epoprostenol, the first approved targeted therapy for pulmonary arterial hypertension (PAH), is also the only one that has shown any benefit for survival vs. placebo in PAH patients [1]. However, its complex route of administration (continuous intravenous infusion) and potentially serious administration-related side effects have limited its use in clinical practice [1,2]. Subsequent prostanoid analogs have had a limited use due to the pain associated with infusion (treprostinil, subcutaneous), frequent dosing (iloprost, inhaled), and prostanoid-associated side effects [2].
